Pioneering the convergence of cellular biology deep technologies & machine learning A.I. to enable mass market adoption of a next generation in disease treatments & human lifespan extension by 15-30 years. We are industrializing cellular human longevity by already dropping production costs of cell-based human blood, biologics, & therapies by two orders of magnitude from $10,000+/L to $100/L. Our four-pillar deep technology platform integrates our market validated replacements for animal serum (FBS) and novel microcarriers with our POC’s for A.I. driven robotic cellular biocomputers & A.I. tools for cellular product isolation, creation, & final therapy enhancing formulas. ​NouBio Inc eliminates the primary bottlenecks needed to scale commercial assets of cellular human longevity drugs & therapies by solving: 1. Prohibitive unit economics: Achieving the “holy grail” price points for mass market adoption. 2. Industrial scalability: From lab to industrial production. 3. Downstream friction: Removing hurdles consuming 40% of bio-manufacturing time. 4. Batch volatility: Stabilizing 300% price fluctuations & variability. NouBio Inc replaces operational losses and prohibitive production costs with scalable, high margin, commercial assets for all of cell-based biomanufacturing. At a potential $10/L cost floor, NouBio Inc converts bio-manufacturing from a cost-prohibitive laboratory struggle into a high-margin industrial powerhouse. NouBio Inc raised venture capital investment from Big Idea Ventures & angels. NouSerum Commercial Validation*: -Tested by over 30 users in 1 year for different cell-based industries -Has 300 serum proteins found in FBS -GRAS category (FDA) -No GMOs -Powder -Antimicrobial *GMP compliant product launch in 2026 Future products: -Cost-effective, bio-degradable microcarriers with no need to remove cells in bioreactors. -AI driven robotic cellular biocomputer to replace bioreactors. -AI formulas for enhanced cell-based products.
